secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001213900-25-041085
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q1 net loss $50.9M, cash $220.7M; Phase 2 data expected June
-------------------------------------------------------------------

- Cash & marketable securities $220.7M, expected to fund operations into Q4 2026.
- Revenue $10.5M, down from $21.6M YoY due to sale of Huntsville facility.
- Net loss $50.9M ($0.24/share) vs $36.8M ($0.19) in Q1 2024; non-GAAP loss $46.4M.
- Topline Phase 2 data for rezpegaldesleukin in atopic dermatitis expected June 2025.
- FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025041085/0001213900-25-041085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025041085/ea0241353-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-041085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer